Can LMWH improve the outcome of patients with inoperable stage III non-small cell lung cancer?

Mehmet Kucukoner; Abdurrahman Isikdogan; Muhammed Ali Kaplan; Ali Inal; Seyit Burhanedtin Zincircioglu; Murtaza Cit; Timucin Cil; Bilgehan Karadayi; Ahmet Dirier; Ismail Yildiz

doi:10.5114/wo.2012.31771

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2012
vol. 16

Send email

Copy url:

abstract:

Original paper

Can LMWH improve the outcome of patients with inoperable stage III non-small cell lung cancer?

Mehmet Kucukoner

,

Abdurrahman Isikdogan

,

Muhammed Ali Kaplan

,

Ali Inal

,

Seyit Burhanedtin Zincircioglu

,

Murtaza Cit

,

Timucin Cil

,

Bilgehan Karadayi

,

Ahmet Dirier

,

Ismail Yildiz

Wspolczesna Onkol 2012; 16 (5): 416–419

DOI: https://doi.org/10.5114/wo.2012.31771

Online publish date: 2012/11/20

View full text Get citation

PlumX metrics:

Aim of the study: Lung cancer is the most common malignancy, accounting for one-third of all deaths from cancer. Some studies have shown that low molecular weight heparin (LMWH) significantly prolongs the survival of patients with non-small cell lung cancer (NSCLC).

The aim of this study was to determine the effects of treating inoperable stage III NSCLC with LMWH in addition to concurrent chemoradiotherapy.

Material and methods: Eighty-two patients with inoperable stage III NSCLC were evaluated at Dicle University’s Medical Oncology Department between 2005 and 2010. All patients were treated with concurrent chemoradiotherapy (CRT) with or without LMWH (enoxaparin 4000 IU/day) depending on the patient’s risk of thrombosis. The primary objectives were to determine disease-free survival (DFS) and overall survival (OS) for patients treated with LMWH.

Results: A total of 38 patients in the LMWH negative group and 44 patients in the LMWH positive group were included in the study. The median OS was 11.2 months for the enoxaparin recipients and 12.7 months for the non-enoxaparin group (p = 0.4). The median DFS was 9.3 months with CRT alone and 10.0 months with CRT plus enoxaparin (p = 0.9). The one-year OS rates were 47% and 34% for groups treated with CRT and enoxaparin plus CRT, respectively, while the two-year OS rates were 23% and 21%, respectively. No significant difference was noted between the two groups in terms of grade 3–4 hematologic toxicity and mucositis (p = 0.3).

Conclusions: This study did not demonstrate improvements in survival for patients with NSCLC treated with enoxaparin. LMWH’s positive contribution is still controversial.

keywords:

Can LMWH improve the outcome of patients with inoperable stage III non-small cell lung cancer?

Mehmet Kucukoner , Abdurrahman Isikdogan , Muhammed Ali Kaplan , Ali Inal , Seyit Burhanedtin Zincircioglu , Murtaza Cit , Timucin Cil , Bilgehan Karadayi , Ahmet Dirier , Ismail Yildiz

non-small cell lung cancer, low molecular weight heparin, chemoradiotherapy

Mehmet Kucukoner

,

Abdurrahman Isikdogan

,

Muhammed Ali Kaplan

,

Ali Inal

,

Seyit Burhanedtin Zincircioglu

,

Murtaza Cit

,

Timucin Cil

,

Bilgehan Karadayi

,

Ahmet Dirier

,

Ismail Yildiz